Patient-reported outcomes measuring an individual’s overall self-rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 trial - Buti, M; Wedemeyer, H; Aleman, S; Chulanov, V; Morozov, V; Sagalova, O; Stepanova, T; Gish, R G; Lloyd, A; Deterding, K; Manuilov, D; Lau, A H; Osinusi, A O; Rock, M; Kim, C; Pandey, S; Singh, B; Lampertico, P (Zeitschrift für Gastroenterologie, 2025)